CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total revenues	$ 0	$ 386	$ 0	$ 868
Costs and Expenses:
Costs of goods sold	0	0	0	47
Research and development	52,923	27,603	111,095	56,446
Sales and marketing	6,346	3,039	14,227	5,405
General and administrative	7,899	22,139	21,494	28,993
Total costs and expenses	67,168	52,781	146,816	90,891
Operating loss	(67,168)	(52,395)	(146,816)	(90,023)
Changes in fair market value of warrant liabilities	0	(58,861)	0	(49,026)
Interest expense	(10,625)	(9,434)	(20,584)	(20,334)
Interest and other income	1,840	3,565	4,043	4,695
Insurance reimbursement	0	342	0	2,272
Foreign currency transaction loss, net	0	(101)	0	(26)
Loss before income tax	(75,953)	(116,884)	(163,357)	(152,442)
Income tax expense	0	(156)	0	(156)
Net loss	(75,953)	(117,040)	(163,357)	(152,598)
Net loss attributable to noncontrolling interest	0	(11)	(67)	(23)
Net loss attributable to Immunomedics, Inc. stockholders	$ (75,953)	$ (117,029)	$ (163,290)	$ (152,575)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)	$ (0.40)	$ (0.68)	$ (0.85)	$ (0.91)
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)	191,745	171,124	191,401	168,583
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ 195	$ 50	$ 186	$ (16)
Unrealized gain (loss) on securities available for sale	0	54	(200)	64
Other comprehensive loss, net of tax:	195	104	(14)	48
Comprehensive loss	(75,758)	(116,936)	(163,371)	(152,550)
Comprehensive loss attributable to noncontrolling interest	0	(11)	(67)	(23)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(75,758)	(116,925)	(163,304)	(152,527)
Product sales
Total revenues	0	0	0	450
License fee and other revenues
Total revenues	0	250	0	265
Research and development
Total revenues	$ 0	$ 136	$ 0	$ 153